We accelerate drug discovery, gene editing, and clinical research to build a healthier future. Our cutting-edge solutions streamline complex bio-tech processes, enabling faster, more efficient breakthroughs.
Get Started
At BioNova, we leverage AI to process vast biological datasets, accelerating the identification of new drug compounds and gene therapies. Our technology enables researchers to make smarter decisions and take faster action, reducing the time and cost of medical development.
Our proprietary algorithms can analyze complex biological data 10x faster than traditional methods, identifying patterns and connections that would be impossible for humans to detect manually.
Accelerated identification of novel drug compounds using AI-powered analysis of biological data.
Precision gene editing solutions powered by machine learning algorithms for enhanced accuracy.
End-to-end support for clinical trials with predictive analytics for improved outcomes.
Our flagship AI-powered drug discovery platform uses deep learning algorithms to analyze molecular structures and predict compound efficacy with 94% accuracy. The platform integrates genomic data, chemical properties, and clinical trial data to identify promising drug candidates.
Advanced gene editing platform that uses machine learning to optimize CRISPR design and minimize off-target effects. Our algorithms analyze thousands of potential guide RNA sequences to identify the most effective and precise options for your research needs.
Comprehensive clinical trial management and analytics platform that uses predictive modeling to optimize trial design, patient recruitment, and outcome analysis. Our AI algorithms identify patterns in patient data to improve trial success rates and reduce costs.
Our AI platform identified a novel compound for treating a rare genetic disorder in just 6 months, a process that typically takes 3-5 years using traditional methods.
By analyzing patient-specific tumor genomics, we developed personalized treatment regimens that improved response rates by 45% compared to standard protocols.
During the recent pandemic, our platform reduced vaccine development time by 60% through rapid antigen screening and optimization.
We've applied our gene editing technology to develop drought-resistant crops, increasing yields by 30% in water-limited environments.
Our NovaDrug AI Platform has received FDA clearance as a Class II medical device for clinical decision support in drug discovery applications.
We have successfully obtained IRB approval for 12 clinical trials across 8 countries, with protocols designed using our AI-powered platform.
Our products comply with EU medical device regulations and have received CE marking for distribution in European markets.
We provide an unmatched competitive edge through faster, more efficient biotechnology solutions. BioNova bridges the gap between research and real-world applications, empowering the next generation of treatments. Join us in revolutionizing healthcare.
Reduce development time by up to 60% with our AI-powered platform
Leverage the latest advancements in AI and machine learning
Work with world-class biologists, data scientists, and AI experts
Meet the brilliant minds behind BioNova's revolutionary biotechnology solutions
Chief Scientific Officer
PhD in Molecular Biology with 5+ years of experience in genetic research and drug discovery.
AI Research Director
Machine learning expert specializing in biological data analysis.
Head of Genomics
Pioneer in CRISPR technology with numerous publications in gene editing research.
Chief Technology Officer
Software architect with expertise in building scalable bioinformatics platforms.